Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML

Blood

Volumn 120, Issue 13, 2012, Pages 2658-2668

  Agarwal, Anupriya ^a   Fleischman, Angela G ^a   Petersen, Curtis L ^a   MacKenzie, Ryan ^a   Luty, Samuel ^a   Loriaux, Marc ^a   Druker, Brian J ^a   Woltjer, Randall L ^b   Deininger, Michael W ^a,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CHEMOKINE RECEPTOR CXCR4; DASATINIB; IMATINIB; PLERIXAFOR; PROTEIN TYROSINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CELL INFILTRATION; CELL MOTILITY; CENTRAL NERVOUS SYSTEM; CHRONIC MYELOID LEUKEMIA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG TREATMENT FAILURE; ENZYME INHIBITION; HISTOPATHOLOGY; LEUKEMIA CELL; LEUKOCYTE COUNT; LIVER WEIGHT; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SPLEEN SIZE; SURVIVAL RATE; TREATMENT RESPONSE;

EID: 84866876169     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-05-355396     Document Type: Article

References (44)

1. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96(10):3343-3356.
2. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-2417. (Pubitemid 44903745)
3. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349(15):1423-1432. (Pubitemid 37211057)
4. Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood. 2007;109(1):58-60. (Pubitemid 46053043)
5. Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99(1):319-325.
6. Chu S, Xu H, Shah NP, et al. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood. 2005;105(5):2093-2098. (Pubitemid 40731797)
7. White DL, Saunders VA, Dang P, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood. 2007;110(12):4064-4072. (Pubitemid 350248463)
8. Mahon FX, Belloc F, Lagarde V, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood. 2003;101(6):2368-2373. (Pubitemid 36304670)
9. Damiano JS, Hazlehurst LA, Dalton WS. Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation. Leukemia. 2001;15(8):1232-1239. (Pubitemid 32776447)
10. Lane SW, Scadden DT, Gilliland DG. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood. 2009;114(6):1150-1157.
11. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 1999;93(5):1658-1667. (Pubitemid 29102494)
12. Dowding C, Guo AP, Osterholz J, Siczkowski M, Goldman J, Gordon M. Interferon-alpha overrides the deficient adhesion of chronic myeloid leukemia primitive progenitor cells to bone marrow stromal cells. Blood. 1991;78(2):499-505.
13. Wertheim JA, Forsythe K, Druker BJ, Hammer D, Boettiger D, Pear WS. BCR-ABL-induced adhesion defects are tyrosine kinase-independent. Blood. 2002;99(11):4122-4130.
14. Sattler M, Salgia R, Shrikhande G, et al. Differential signaling after beta1 integrin ligation is mediated through binding of CRKL to p120(CBL) and p110(HEF1). J Biol Chem. 1997;272(22):14320-14326. (Pubitemid 27232846)
15. Salgia R, Quackenbush E, Lin J, et al. The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha. Blood. 1999;94(12):4233-4246.
16. Ptasznik A, Urbanowska E, Chinta S, et al. Crosstalk between BCR/ABL oncoprotein and CXCR4 signaling through a Src family kinase in human leukemia cells. J Exp Med. 2002;196(5):667-678. (Pubitemid 35024444)
17. Geay JF, Buet D, Zhang Y, et al. p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression. Cancer Res. 2005;65(7):2676-2683. (Pubitemid 40490067)
18. Jin L, Tabe Y, Konoplev S, et al. CXCR4 upregulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol Cancer Ther. 2008;7(1):48-58.
19. Agarwal A, O'Hare T, Deininger MW. CXCR4 antagonists for the treatment of CML. In: Novel Developments in Stem Cell Mobilization: Focus on CXCR4. New York, NY: Springer; 2012:351-367.
20. Kucia M, Reca R, Miekus K, et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells. 2005;23(7):879-894. (Pubitemid 41170944)
21. Devine SM, Flomenberg N, Vesole DH, et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol. 2004;22(6):1095-1102. (Pubitemid 41095043)
22. Liles WC, Broxmeyer HE, Rodger E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood. 2003;102(8):2728-2730. (Pubitemid 37248839)
23. DiPersio JF, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113(23):5720-5726.
24. Azab AK, Runnels JM, Pitsillides C, et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood. 2009;113(18):4341-4351.
25. Nervi B, Ramirez P, Rettig MP, et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood. 2009;113(24):6206-6214.
26. Zeng Z, Shi YX, Samudio IJ, et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood. 2009;113(24):6215-6224.
27. Tavor S, Eisenbach M, Jacob-Hirsch J, et al. The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation. Leukemia. 2008;22(12):2151-2158.
28. Agarwal A, Bumm TG, Corbin AS, et al. Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease. Blood. 2008;112(5):1960-1970.
29. Luo FR, Yang Z, Camuso A, et al. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin Cancer Res. 2006;12(23):7180-7186. (Pubitemid 44974520)
30. Hendrix CW, Flexner C, MacFarland RT, et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother. 2000;44(6):1667-1673. (Pubitemid 30340812)
31. Juarez J, Dela Pena A, Baraz R, et al. CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment. Leukemia. 2007;21(6):1249-1257. (Pubitemid 46831814)
32. Weisberg E, Azab AK, Manley PW, et al. Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib. Leukemia. 2012;26(5):985-990.
33. Wolff NC, Ilaria RL Jr. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. Blood. 2001;98(9):2808-2816.
34. de Jong R, Haataja L, Voncken JW, Heisterkamp N, Groffen J. Tyrosine phosphorylation of murine Crkl. Oncogene. 1995;11(8):1469-1474.
35. Chien SZX, Papayannopoulou T, Appelbaum FR, Becker PS. The CXCR4 inhibitor plerixafor effectively mobilizes primary AML in NODscid IL2R c-/- xenografts and markedly reduces but does not eradicate leukemia in combination with cytarabine +/- clofarabine chemotherapy. Am Soc Hematol. 2011;1432.
36. Wolff NC, Richardson JA, Egorin M, Ilaria RL Jr. The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia. Blood. 2003;101(12):5010-5013. (Pubitemid 36857766)
37. Burger JA, Burkle A. The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target. Br J Haematol. 2007;137(4):288-296. (Pubitemid 46650259)
38. Parameswaran R, Yu M, Lim M, Groffen J, Heisterkamp N. Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist. Leukemia. 2011;25(8):1314-1323.
39. Fei F, Stoddart S, Muschen M, Kim YM, Groffen J, Heisterkamp N. Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia. Leukemia. 2010;24(4):813-820.
40. Porkka K, Koskenvesa P, Lundan T, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood. 2008;112(4):1005-1012.
41. Weisberg E, Wright RD, McMillin DW, et al. Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells. Mol Cancer Ther. 2008;7(5):1121-1129.
42. Burrell K, Jelveh S, Jalali S, Hill R, Zaden G. Role of bone marrow derived cells in response to ionizing radiation in normal brain [abstract]. Presented at AACR 2011 Annual Meeting. April 3, 2011. Orlando, FL. Abstract 566.
43. Genzyme. Mozobil (plerixafor injection) product monograph. Cambridge, MA: Genzyme; 2009.
44. Uy GL, Rettig MP, Motabi IH, et al. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood. Apr 26;119(17):3917-3924.